These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 39018782)
1. PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia. Kong C; Wu M; Lu Q; Ke B; Xie J; Li A Leuk Res; 2024 Sep; 144():107548. PubMed ID: 39018782 [TBL] [Abstract][Full Text] [Related]
2. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164 [TBL] [Abstract][Full Text] [Related]
3. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949 [TBL] [Abstract][Full Text] [Related]
4. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia. Wiśniewski K; Puła B Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284 [TBL] [Abstract][Full Text] [Related]
5. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730 [TBL] [Abstract][Full Text] [Related]
6. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Aslan B; Manyam G; Iles LR; Tantawy SI; Desikan SP; Wierda WG; Gandhi V Blood Adv; 2024 Sep; 8(17):4487-4501. PubMed ID: 38968154 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427 [TBL] [Abstract][Full Text] [Related]
9. New Means and Challenges in the Targeting of BTK. Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606 [TBL] [Abstract][Full Text] [Related]
10. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679 [No Abstract] [Full Text] [Related]
11. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Geethakumari PR; Awan F Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907 [No Abstract] [Full Text] [Related]
13. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282 [TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464 [TBL] [Abstract][Full Text] [Related]
15. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Guo A; Lu P; Coffey G; Conley P; Pandey A; Wang YL Oncotarget; 2017 Feb; 8(8):12953-12967. PubMed ID: 28088788 [TBL] [Abstract][Full Text] [Related]
16. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227 [TBL] [Abstract][Full Text] [Related]
17. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. Javidi-Sharifi N; Brown JR Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995 [TBL] [Abstract][Full Text] [Related]
18. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Rhodes JM; Mato AR Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166 [TBL] [Abstract][Full Text] [Related]
19. Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies. Schultze MD; Reeves DJ Ann Pharmacother; 2024 Oct; 58(10):1064-1073. PubMed ID: 38235739 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia. Woyach JA Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341 [No Abstract] [Full Text] [Related] [Next] [New Search]